Arcus Biosciences
Market cap $2.36B 144.0M shares (10-Q, Oct 29, 2026) × $16.39 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- PEAK-1 / PEAK-20 enrollment doneYear-end 2026PEAK-1 / PEAK-20 enrollment done, Year-end 2026, notable
- I&I portfolio MRGPRX2 antagonist trialLate 2026 / Early 2027I&I portfolio MRGPRX2 antagonist trial, Late 2026 / Early 2027, routine
- quemliclustat Ph3 interim4Q 2026quemliclustat Ph3 interim, 4Q 2026, material
- ARC-20 cohorts cas+axitinib trial start4Q 2026ARC-20 cohorts cas+axitinib trial start, 4Q 2026, notable
- PEAK-20 trial start4Q 2026PEAK-20 trial start, 4Q 2026, notable
- PEAK-1 enrollment done4Q 2026PEAK-1 enrollment done, 4Q 2026, routine
- TNFR1 inhibitor RA trial startearly 2027TNFR1 inhibitor RA trial start, early 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
quemliclustat
zimberelimab
domvanalimab
AB102
AB801
- Undisclosed indication
AB598
- Undisclosed indication
Discontinued (3)
- domvanalimab — Non-Small Cell Lung Cancer · futility at interim — domvanalimab-based combination did not improve OS vs pembrolizumab plus chemotherapy
- domvanalimab — Gastric Cancer · discontinued due to futility in Phase 3 STAR-221 trial
- etrumadenant — undisclosed · Gilead terminated its rights to etrumadenant (the adenosine receptor antagonist program) in the second-quarter 2025
Capital (as filed)
- Cash
- $151M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $479M Sep 30, 2026
- Long-term investments
- $64.0M Sep 30, 2026
- Operating cash flow
- −$88.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $694M cash, runway 2029 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-10-22 424B5 · Priced offering 14.3M shares · at $17.50 · $250M gross · 8.4% below the prior close ($19.10, Oct 21, 2026)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-05 UPDATE: Arcus Biosciences (RCUS) - The Pancreas Gets a Date 🔒 Paid
- 2026-10-24 UPDATE: Arcus Biosciences (RCUS) - The Deal Prices, the Greenshoe Goes 🔒 Paid
- 2026-10-22 UPDATE: Arcus Biosciences (RCUS) - The Dilution Gap Opens ★ Distilled Pro
- 2026-10-20 UPDATE: Arcus Biosciences (RCUS) - The Trigger Fires ★ Distilled Pro
- 2026-08-06 UPDATE: Arcus Biosciences (RCUS) - Gilead Leaves the Boardroom, the Trigger Slips to Fall 🔒 Paid
- 2026-07-22 UPDATE: Arcus Biosciences (RCUS) - Two More Partners in One Day, and the Backbone Pitch Stops Being a Pitch 🔒 Paid
- 2026-06-03 UPDATE: Arcus Biosciences (RCUS) - The Bispecific Bet Gets a Second Swing 🔒 Paid
- 2026-05-05 UPDATE: Arcus Biosciences (RCUS) - The TKI-Free Bet Gets Its First Receipt 🔒 Paid
- 2026-04-27 UPDATE: Arcus Biosciences (RCUS) - Gilead Walks Further Away, TIGIT Officially Dies, Stock Rips +25% 🔒 Paid
- 2026-03-02 UPDATE: Arcus Biosciences (RCUS) - The Catalyst Wrap-Up 🔒 Paid
- 2026-02-25 Arcus Biosciences (RCUS): Scientific Deep Dive for Casdatifan and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Arcus Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-25 Watch Arcus Biosciences (RCUS): Scientific Deep Dive for Casdatifan and Pipeline Products Casdatifan shows strong single-agent efficacy but unproven safety in IO combinations after the AstraZeneca trial pause, making RCUS a speculative turnaround play best watched until mid-2026 combination data arrives.
- 2026-03-02 Hold UPDATE: Arcus Biosciences (RCUS) - The Catalyst Wrap-Up Casdatifan single-agent efficacy is durable and management is pivoting to TKI-free combinations to avoid toxicity, but mid-2026 combination safety data is still needed before upgrading to BUY.
- 2026-04-27 Hold UPDATE: Arcus Biosciences (RCUS) - Gilead Walks Further Away, TIGIT Officially Dies, Stock Rips +25% TIGIT is fully dead removing R&D drag, casdatifan efficacy remains durable, and cash is fortress-like, but the mid-2026 combination safety data is still the trigger to upgrade to outright BUY; accumulate on dips into the mid-$20s.
- 2026-05-05 Hold UPDATE: Arcus Biosciences (RCUS) - The TKI-Free Bet Gets Its First Receipt eVOLVE-RCC02 is permanently buried, the TKI-free pivot has a first credible datapoint (7% primary progression in n=30), and I&I assets have clinic dates, but the mid-2026 cas+cabo ARC-20 readout remains the trigger to upgrade to outright BUY.
- 2026-06-03 Speculative buy speculative UPDATE: Arcus Biosciences (RCUS) - The Bispecific Bet Gets a Second Swing BMS stepping in with a PD-L1/VEGF-A bispecific restores front-line combination optionality lost with eVOLVE, the monotherapy-trap bear case keeps weakening, and the stock has pulled back to the low-$20s accumulation range, though the mid-2026 cas+cabo readout remains the gate to outright BUY.
- 2026-07-22 Speculative buy speculative UPDATE: Arcus Biosciences (RCUS) - Two More Partners in One Day, and the Backbone Pitch Stops Being a Pitch Two same-day partnerships (AVEO tivozanib randomized cohort and Summit ivonescimab) confirm casdatifan as a genuine backbone asset with five combination partners, but the mid-2026 cas+cabo ARC-20 data remains the gate to outright BUY and the stock at $29.97 has priced in much of the backbone thesis.
- 2026-08-06 Speculative buy speculative UPDATE: Arcus Biosciences (RCUS) - Gilead Leaves the Boardroom, the Trigger Slips to Fall PACIFIC-8 death removes last TIGIT drain, Gilead board exit reads as post-TIGIT housekeeping that simplifies M&A plumbing, PEAK-20 names the 1L bet, but the upgrade trigger slipped from mid-2026 to 2H 2026 with ≥18-month follow-up bar and the cas+zim+ipi safety read is a new gate.
- 2026-10-20 Buy core UPDATE: Arcus Biosciences (RCUS) - The Trigger Fires The cas+cabo ARC-20 trigger set in the original deep dive has fired: 14.5-month mPFS vs ~10 months for cabo alone and 77% vs ~60% 18-month OS, front-line data holds up, and PEAK-20 is on track, making the stock at $23.75 a de-risked Phase 1b dataset below its pre-data trading levels.
- 2026-10-22 Buy core UPDATE: Arcus Biosciences (RCUS) - The Dilution Gap Opens The clinical case is untouched after the offering announcement, the raise funds the three-Phase-3 plan rather than rescuing the balance sheet, but readers on the sidelines should let the deal price before acting given the fresh overhang.
- 2026-10-24 Buy core UPDATE: Arcus Biosciences (RCUS) - The Deal Prices, the Greenshoe Goes The offering priced at a tight 8.4% discount with the full greenshoe exercised, confirming real institutional demand; pro forma cash of ~$960M funds three registrational trials, and the condition to act for sidelined readers has been met.
- 2026-11-05 Buy core UPDATE: Arcus Biosciences (RCUS) - The Pancreas Gets a Date Casdatifan thesis is untouched and better funded with ~$960M pro forma cash and runway into 2029; Pfizer joining bispecific cohorts confirms backbone thesis; PRISM-1 interim moves into Q4 2026 adding a near-term binary but casdatifan still drives the valuation.
- Long call · opened Jun 4, 2026 at $24.69 · -33.6% vs XBI +8.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (33)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 4, 2026ReleaseArcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pi...→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings confirm the fortress balance sheet now reaches into 2029 post-offering, Arcus named a fifth bispecific partner (Pfizer's tivunatamig), and the PRISM-1 interim analysis in pancreatic cancer is now expected this quarter — a binary catalyst I flagged as a "synthetic-control-arm coin flip" that has been quietly approaching.
- Nov 4, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseArcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2...
- Oct 23, 20268-KCurrent report: other events→ BD updateThe Arcus offering priced Tuesday night at $17.50/share and closed today with the greenshoe exercised in full — 16.4M shares sold, ~$269.7M in net proceeds, and the institutional bid answered at the offer price.
- Oct 22, 2026ReleaseArcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stockvia aggregator
- Oct 22, 2026424B5Prospectus supplement (offering)
- Oct 21, 2026ReleaseArcus Biosciences Announces Commencement of Public Offering of Common Stock→ BD update
- Oct 21, 2026ReleaseArcus Biosciences Announces Pricing of $250 Million Public Offering of Common St...→ BD update
- Oct 21, 20268-KCurrent report: results of operations→ BD update
- Oct 21, 2026424B5Prospectus supplement (offering)→ BD update
- Oct 20, 2026ReleaseArcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdati...→ BD updateBD extracted 1 program update from this document → RCUS pipeline
- Oct 20, 20268-KCurrent report: other events→ BD update
- Sep 22, 2026ReleaseArcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a ...BD extracted 1 program update from this document → RCUS pipeline
- Aug 26, 2026ReleaseArcus Biosciences to Participate in Three Upcoming Investor Conferences
- Aug 7, 2026SCHEDULE 13D/A13D amendment
- Aug 5, 2026ReleaseArcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a P...BD extracted 1 program update from this document → RCUS pipeline
- Aug 5, 20268-KCurrent report: results of operations · EX-99.1BD extracted 2 program updates from this document → RCUS pipeline
- Aug 5, 202610-QQuarterly report
- Jul 22, 2026ReleaseArcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Eval...
- Jul 22, 2026ReleaseArcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboratio...BD extracted 1 program update from this document → RCUS pipeline
- Jul 21, 2026ReleaseArcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financi...
- Jul 1, 2026ReleaseNew Research Published in Nature Links Clinical Activity with HIF‑2a Biology in ...BD extracted 1 program update from this document → RCUS pipeline
- Jun 12, 20268-KCurrent report: shareholder vote
- Jun 3, 2026ReleaseArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to...BD extracted 1 program update from this document → RCUS pipeline
- May 26, 2026ReleaseArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthc...
- May 5, 2026ReleaseArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pi...
- May 5, 20268-KCurrent report: results of operations · EX-99.1
- May 5, 202610-QQuarterly report
- Apr 21, 2026DEFA14AProxy soliciting material
- Apr 21, 2026DEF 14AProxy statement
- Apr 20, 20268-KCurrent report: other events
- Mar 23, 20268-KCurrent report: officer / director change
3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Sep 28, 2026CT ORDERCT ORDER
- Apr 21, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment